The pivotal phase III trial by Apfel et al. randomized 1019 patients with diabetic polyneuropathy to subcutaneous recombinant human NGF (rhNGF, 0.1 μg/kg, n = 504) or placebo (n = 515), administered three times weekly for 48 weeks. Here, NGF is linked to diabetic polyneuropathy.